Huang Jia Qing, Sridhar Subbaramiah, Hunt Richard H
Division of Gastroenterology, Department of Medicine, McMaster University Medical Center, 1200 Main Street West, Room 4W8, Ontario L8N 3Z8, Hamilton, Canada.
Lancet. 2002 Jan 5;359(9300):14-22. doi: 10.1016/S0140-6736(02)07273-2.
The relation between H pylori infection and use of non-steroidal anti-inflammatory drugs (NSAIDs) in the pathogenesis of peptic-ulcer disease is controversial. We undertook a meta-analysis to address this issue.
By computer and manually we sought observational studies on the prevalence of peptic-ulcer disease in adult NSAID takers or the prevalence of H pylori infection and NSAID use in patients with peptic-ulcer bleeding. Summary odds ratios were calculated from the raw data. Tests for homogeneity were done.
Of 463 citations identified, 25 studies met inclusion criteria. In 16 studies of 1625 NSAID takers, uncomplicated peptic-ulcer disease was significantly more common in patients positive than in those negative for H pylori (341/817 [41.7%] vs 209/808 [25.9%]; odds ratio 2.12 [95% CI 1.68-2.67]). In five controlled studies, peptic-ulcer disease was significantly more common in NSAID takers (138/385 [35.8%]) than in controls (23/276 [8.3%]), irrespective of H pylori infection. Compared with H pylori negative individuals not taking NSAIDs, the risk of ulcer in H pylori infected NSAID takers was 61.1 (9.98-373). H pylori infection increased the risk of peptic-ulcer disease in NSAID takers 3.53-fold in addition to the risk associated with NSAID use (odds ratio 19.4). Similarly, in the presence of risk of peptic-ulcer disease associated with H pylori infection (18.1), use of NSAIDs increased the risk of peptic-ulcer disease 3.55-fold. H pylori infection and NSAID use increased the risk of ulcer bleeding 1.79-fold and 4.85-fold, respectively. However, the risk of ulcer bleeding increased to 6.13 when both factors were present.
Both H pylori infection and NSAID use independently and significantly increase the risk of peptic ulcer and ulcer bleeding. There is synergism for the development of peptic ulcer and ulcer bleeding between H pylori infection and NSAID use. Peptic-ulcer disease is rare in H pylori negative non-NSAID takers.
幽门螺杆菌感染与使用非甾体抗炎药(NSAIDs)在消化性溃疡病发病机制中的关系存在争议。我们进行了一项荟萃分析以解决该问题。
通过计算机检索和人工检索,我们查找了关于成年NSAIDs服用者消化性溃疡病患病率,或消化性溃疡出血患者中幽门螺杆菌感染率及NSAIDs使用情况的观察性研究。从原始数据计算汇总比值比。进行了同质性检验。
在识别出的463篇文献中,25项研究符合纳入标准。在16项针对1625名NSAIDs服用者的研究中,幽门螺杆菌阳性患者中无并发症的消化性溃疡病明显比阴性患者更常见(341/817 [41.7%] 对209/808 [25.9%];比值比2.12 [95% CI 1.68 - 2.67])。在5项对照研究中,NSAIDs服用者中消化性溃疡病明显比对照组更常见(138/385 [35.8%]),而与幽门螺杆菌感染无关。与未服用NSAIDs的幽门螺杆菌阴性个体相比,感染幽门螺杆菌的NSAIDs服用者发生溃疡的风险为61.1(9.98 - 373)。幽门螺杆菌感染使NSAIDs服用者消化性溃疡病的风险除了与使用NSAIDs相关的风险外又增加了3.53倍(比值比19.4)。同样,在存在与幽门螺杆菌感染相关的消化性溃疡病风险(18.1)时,使用NSAIDs使消化性溃疡病的风险增加了3.55倍。幽门螺杆菌感染和使用NSAIDs分别使溃疡出血的风险增加了1.79倍和4.85倍。然而,当两种因素都存在时,溃疡出血的风险增加到6.13。
幽门螺杆菌感染和使用NSAIDs均独立且显著增加消化性溃疡和溃疡出血的风险。幽门螺杆菌感染与使用NSAIDs在消化性溃疡和溃疡出血的发生上存在协同作用。在幽门螺杆菌阴性且未服用NSAIDs的个体中,消化性溃疡病罕见。